You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Augmentin logo

Product menu

Amoxicillin-clavulanate: Continues to demonstrate favourable susceptibility against common pathogens of community-acquired infections*

Demonstrated in vitro susceptibility means that 90%-95% of your patients can expect to have a favourable therapeutic response.1

augmentin_2020_soar_logo_1

Survey of Antibiotic resistance (SOAR)

SOAR is an ongoing surveillance study monitoring antimicrobial resistance in the Middle East, Africa, Latin America, Asia-Pacific and the Commonwealth of Independent States countries, since 2002. Antimicrobial susceptibility of key respiratory pathogens (Streptococcus pneumoniae and Haemophilus influenzae) are being monitored to map the current local antimicrobial susceptibility patterns of these pathogens.2-11

SOAR helps in understanding local pathogen resistance to guide appropriate antibiotic prescription.3

SOAR’s robust and reliable susceptibility data collected from2-11:

isolates
augmentin_2000img
centres_countries
25 centers

How does SOAR monitor antibiotic susceptibility?

Clinical respiratory isolates were collected from patients with community-acquired respiratory tract infections. Organisms in the isolates are identified using conventional methods and minimum inhibitory concentrations (MIC) determined for the following antibiotics:2,4-11

  • Amoxicillin-clavulanate
  • Macrolides (azithromycin, clarithromycin, erythromycin)
  • Cephalosporins (cefaclor, cefixime, ceftriaxone, cefpodoxime, cefuroxime)
  • Fluoroquinolones (levofloxacin, moxifloxacin)
  • Clindamycin
  • Penicillin (ampicillin, amoxicillin)
  • Trimethoprim/sulfamethoxazole

Susceptibility testing was done using MIC breakpoints based on Clinical and Laboratory Standards Institute and/or European Committee on Antimicrobial Susceptibility Testing criteria.2,4-11

Amoxicillin-clavulanate: Still going strong, 40 years

Antimicrobial susceptibility of key respiratory tract pathogens*

Choose with confidence an antibiotic with favourable susceptibility against S. pneumoniae & H. influenzae.*14

Resjstant pathogens are likely to be found in children <2 years of age13

pnuemoniae_graph

*The table/image has been independently created by GSK from information in the publication.
*Susceptibility patterns may vary with time and geography. Always refer to local susceptibility data before prescribing. The most recent local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
†Data presented only for select antibiotics as per CLSI breakpoints. For a full list of antibiotics refer to the original  publication. Isolates were collected from various samples like sputum, blood, transtracheal aspirates, bronchoalveolar lavage, sinus or middle ear fusion.
CLSI: Clinical and Laboratory Standards Institute.

augmentin_2020_soar_logo_1

Antimicrobial surveillance: 30 years of commitment to deliver high quality susceptibility data3

The SOAR programme is a follow-up of the Alexander Project to monitor antibiotic susceptibility that ran from 1992 to 2001 across 26 countries and successfully published over 46 papers of the robust data that it generated.

sciflix sciflix

Augmentin | Stringent Manufacturing
Processes for Reliable Quality

Watch Now

Explore SCI-FLIX Playlist

Need help with this product?

Request a contact

Stay Informed

Request a rep

Augmentin Safety Information15-19

Contraindications:

AUGMENTIN is contra-indicated in patients with a history of hypersensitivity to betalactams, e.g., penicillins and cephalosporins.

AUGMENTIN is contra-indicated in patients with a previous history of AUGMENTIN associated jaundice/hepatic dysfunction.

Warnings and precautions:

Before initiating therapy with AUGMENTIN, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens.

Prolonged use may result in overgrowth of non-susceptible organisms.

AUGMENTIN should be used with caution in patients with evidence of hepatic dysfunction.

No dosing recommendations can be made for AUGMENTIN ES in renally impaired patients.

AUGMENTIN use should be avoided in pregnancy, especially during the first trimester, unless considered essential by the physician.

AUGMENTIN may be administered during the period of lactation.

Adverse Events:

Mucocutaneous candidiasis, diarrhoea, nausea, vomiting.

References

  1. Doern GV, Brecher SM. The Clinical Predictive Value (or Lack Thereof) of the Results of In vitro Antimicrobial Susceptibility Tests. J Clin Microbiol 2011;49(9_Suppl):S11-4.
  2. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i76-i87.
  3. GSK - Survey of Antibiotic Resistance (SOAR) - AMR Industry Alliance. AMR Industry Alliance. Available at: https://www.amrindustryalliance.org/case-study/gsks-survey-of-antibiotic-resistance-soar. Last accessed: 23 November 2022.
  4. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i2-i18.
  5. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Greece. J Antimicrob Chemother 2018;73(Suppl 5):v36–v42.
  6. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016–18 in Vietnam, Cambodia, Singapore and the Philippines: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1): i19-i42.
  7. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Latin America (Argentina, Chile and Costa Rica): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i43-i59.
  8. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in the Middle East (Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i60-i75.
  9. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i88-i99.
  10. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i100-i111.
  11. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2012–14 in Thailand, India, South Korea and Singapore. J Antimicrob Chemother 2016;71 Suppl 1: i3–i19.
  12. Clinical & Laboratory Standards Institute. M100, Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition. Available from: edaptivedocs.net. Last accessed 15 August 2022.
  13. Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J 2000; 19(9):911-6.
  14. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in the Middle East(Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i60-i75.
  15. Augmentin BID Tablets Prescribing Information. Kindly refer to the latest PI approved by SFDA for Augmentin.
  16. Augmentin TID Tablets Local Prescribing Information. Kindly refer to the latest PI approved by SFDA for Augmentin.
  17. Augmentin ES 600 Local Prescribing Information. Kindly refer to the latest PI approved by SFDA for Augmentin.
  18. Augmentin BID Suspension Local Prescribing Information. Kindly refer to the latest PI approved by SFDA for Augmentin.
  19. Augmentin TID Suspension Local Prescribing Information. Kindly refer to the latest PI approved by SFDA for Augmentin.

GSK does not recommend, endorse or accept liability for sites controlled by a third party.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com

Trade marks are owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies or its licensor.

PM-SA-ACA-WCNT-230001 Date of preparation: October 2024